MannKind Corp. has received word that the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee is tentatively scheduled on April 1, 2014 to review the company’s NDA for Afrezza (insulin human [rDNA origin]) Inhalation Powder. The date and details of the meeting are subject to confirmation by the FDA in a Federal Register notice.   MannKind resubmitted the NDA on October 13, 2013 seeking approval to market Afrezza in the U.S. with an indication to improve glycemic control i...